Page 27 - Sun Pharma

Here's why Sun Pharma is betting on Japan when peers are losing interest

Recently, Japan's sixth largest generic player Lupin said it felt that the annual price cuts made the market unattractive and it would continue to grow in single digits in value terms

Top 10 biz headlines: Sun Pharma, I-T dept seeks tax mop-up, and more

From PSU general insurance companies to Piramal's financial commitments, here are the top 10 business headlines for the day

Sun Pharmaceutical bullish on Japanese market as peers lose interest

Most Indian players have exited Japan over the past decade. Ranbaxy was one of the early entrants.

Sun Pharma posts Rs 1,433-crore pre-tax profit in Q2, meets estimates

Mumbai, 7 NovemberSun Pharmaceutical Industries' second quarter (Q2; July-September) results are mostly in line with Street expectations, with pre-tax profit of Rs 1,433.4 crore. It was Rs 111.9 crore in the corresponding quarter last year that was impacted by settlements related to anti-trust litigation on its Modafinil drug in the US. Net profit for the quarter is Rs 1,064 crore, with resulting net profit margin at 13.4 per cent. This is against a net loss of Rs 269.6 crore a year before. Adjusted for the exceptional item of Rs 1,214 crore for Q2 last year (Modafinil settlement), net profit growth was 12.6 per cent, the company said. Sales or income from operations was Rs 7,949 crore, up 16 per cent year-on-year (YoY). The India business saw 35 per cent growth YoY to Rs 2,515 crore, while US finished dosage sales remained flat YoY at $339 million. Taro, the US subsidiary, had sales of $161 mn, up one per cent over Q2 last year. Emerging market sales grew only three per cent to ...

Sun Pharma ties up with AstraZeneca to sell novel oncology drugs in China

Sun Pharma has been working out deals through this year to gain foothold in the Chinese market

Sun Pharma climbs over 5% on deal with AstraZeneca, pares gains later

The agreement will be announced later in the day at the China International Import Expo (CIIE) in Shanghai.

Sun Pharma, Britain's AstraZeneca join to distribute cancer drugs in China

The financial terms of the agreement, which has an initial tenure of 10 years, were not disclosed

Specialty drugs essential for re-rating of Sun Pharma stock, say analysts

Analysts say, Tuesday's launch of ophthalmic specialty product Cequa can achieve peak sales of $100-125 million per annum

Sun Pharmaceutical launches Cequa to treat dry eye disease in US market

Cequa is indicated to increase tear production in patients with dry eye, Sun Pharma said

Symptoms of success

Soma Das has been able to capture brilliantly the essence of Dilip Shanghvi through countless stories

Sun Pharma slides 4% after Co says forensic audit by Sebi underway

A forensic audit has been ordered by Sebi w.r.t. the financial statements of the company for the financial years ending FY16, FY17, and FY18.

Sebi orders forensic audit of Sun Pharma financial statements from FY16-18

Sun Pharma, however, did not provide any specific details on the reasons for the Securities and Exchange Board of India to order the forensic audit

Sun Pharma slides 4% on report of Sebi ordering forensic audit

The audit has been ordered based on allegations of corporate governance and tax-related offences and securities market-related violations by the company

Sun Pharma gains 5% as Sebi finds no merit in allegation of fraud

HDFC Securities has 'buy' rating on Sun Pharma with a 12-month target price of Rs 545 as the brokerage expects a recovery in the profitability (24 per cent margin) by FY21E.

Sebi inquiry clears Sun Pharma, finds no merit in allegations of fraud

The investigation team is of the view that the matter does not require further probe, said sources. The team sent its report to the Sebi committee for vetting

Sun Pharmaceutical's US specialty ramp-up still slow, say experts

Sun's focus on specialty comes at a time when its US revenues are under pressure owing to competitive intensity

Sun Pharma announces tie-up for China foray; to develop 8 generic products

The total addressable market size for all these eight products is about $1 billion (according to recent IQVIA data) in mainland China

Sun Pharma signs global licensing pact with CSIR-IICT for patents

The pact is for patents related to certain compounds with potential therapeutic activity across multiple indications

Nifty Pharma index hits 5-year low; Glenmark at 7-year low post Q1 results

Glenmark Pharmaceuticals plunged 9 per cent, while Dr Reddy's slipped 8 per cent in intra-day trade

Global business growth, lower costs a booster dose for Sun Pharma

Company focusing on specialty portfolio to drive US growth